AccScience Publishing / BH / Online First / DOI: 10.36922/bh.3515
Submit to BH
Cite this article
8
Download
317
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
REVIEW

Characteristics and prognosis of patients with cardiac sarcoidosis presenting with atrioventricular block and ventricular arrhythmias

Caleb Carver1* ,  Raheel Ahmed2
Show Less
1 Department of Medicine, Gold Coast University Hospital, Southport, Queensland, Australia
2 Department of Cardiology, Royal Brompton and Harefield Hospitals, London, United Kingdom
Brain & Heart, 3515 https://doi.org/10.36922/bh.3515
Submitted: 27 April 2024 | Accepted: 19 August 2024 | Published: 8 October 2024
© 2024 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
Abstract

Cardiac sarcoidosis (CS) may initially present with life-threatening arrhythmias such as atrioventricular block (AVB) and ventricular arrhythmia (VA), including ventricular tachycardia and ventricular fibrillation. Diagnosing CS is challenging due to subtle or absent findings in routine tests and the low sensitivity of the definitive diagnostic tool, endomyocardial biopsy. CS can also mimic other cardiac conditions such as dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy, and it may occur without any systemic involvement. Consequently, delays in presentation, accurate diagnosis, and initiation of appropriate treatment are frequent. Greater awareness of the condition could improve outcomes for patients with CS. Non-invasive advanced imaging techniques, such as 18F-fluorodeoxyglucose positron emission tomography and cardiac magnetic resonance imaging are essential for diagnosis, although they may not be accessible in all clinical settings. Management of arrhythmias in CS involves conventional therapies in the utilization of antiarrhythmics and non-pharmacological therapy (e.g., implantable devices), but with notable divergences in the use of immunosuppression and a preference for implantable cardioverter defibrillators over permanent pacemakers. This narrative review aimed to outline the clinical features of patients with CS presenting with AVB or VA and examine diagnostic investigations, imaging techniques, treatment approaches, and prognosis based on current research and international guidelines.

Keywords
Cardiac sarcoidosis
Sarcoidosis
Atrioventricular block
Ventricular tachycardia
Ventricular fibrillation
Sudden cardiac death
Funding
None.
Conflict of interest
The authors declare that they have no competing interests.
References
  1. Sarcoidosis UK. Sarcoidosis and the Heart; 2022. Available from: https://www.sarcoidosisuk.org/information-hub/ sarcoidosis-heart [Last accessed on 2022 Sep 11].

 

  1. Cardiac Sarcoidosis-American College of Cardiology; 2022. Available from: https://www.acc.org/latest-in-cardiology/ articles/2021/05/20/13/01/cardiac-sarcoidosis [Last accessed on 2022 Sep 11].

 

  1. Markatis E, Afthinos A, Antonakis E, Papanikolaou IC. Cardiac sarcoidosis: Diagnosis and management. Rev Cardiovasc Med. 2020;21:321-338. doi: 10.31083/j.rcm.2020.03.102

 

  1. Ahmed, R, Shahbaz, H, Ramphul, K, et al. Racial disparities among patients with cardiac sarcoidosis and arrhythmias in the United States: A propensity matched-analysis from the National Inpatient Sample Database 2016-2020. Curr Probl Cardiol. 2024;49(4):102450. doi: 10.1016/j.cpcardiol.2024.102450

 

  1. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119:167-172.

 

  1. Ekström K, Lehtonen J, Nordenswan HK, et al. Sudden death in cardiac sarcoidosis: An analysis of nationwide clinical and cause-of-death registries. Eur Heart J. 2019;40:3121-3128. doi: 10.1093/eurheartj/ehz428

 

  1. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969-1977. doi: 10.1161/CIRCULATIONAHA.109.851352

 

  1. Ahmed, R, Sawatari, H, Amanullah, K, et al. Characteristics and outcomes of hospitalized patients with heart failure and sarcoidosis: A propensity-matched analysis of the Nationwide Readmissions Database 2010-2019. Am J Med. 2024;137:751-760.e8. doi: 10.1016/j.amjmed.2024.03.039

 

  1. Rosenthal DG, Fang CD, Groh CA, et al. Heart failure, atrioventricular block, and ventricular tachycardia in sarcoidosis. J Am Heart Assoc. 2021;10:e017692. doi: 10.1161/JAHA.120.017692

 

  1. Hoogendoorn JC, Ninaber MK, Piers SRD, et al. The harm of delayed diagnosis of arrhythmogenic cardiac sarcoidosis: A case series. Eurospace. 2020;22:1376-1383. doi: 10.1093/europace/euaa115

 

  1. Nery PB, Beanlands RS, Nair GM, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol. 2014;25:875-881. doi: 10.1111/jce.12401

 

  1. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol. 2011;4:303-309. doi: 10.1161/CIRCEP.110.959254

 

  1. Terasaki F, Azuma A, Anzai T, et al. JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis-digest version. Circ J. 2019;83(11):2329-2388. doi: 10.1253/circj.cj-19-0508

 

  1. Judson MA, Costabel U, Drent M, et al. The WASOG sarcoidosis organ assessment instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014;18:19-27.

 

  1. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;7:1304-1323. doi: 10.1016/j.hrthm.2014.03.043

 

  1. Lee S, Birnie D, Dwivedi G. Current perspectives on the immunopathogenesis of sarcoidosis. Respir Med. 2020;173:106161. doi: 10.1016/j.rmed.2020.106161

 

  1. Williams O, Fatima S. Granuloma. Treasure Island, FL: StatPearls Publishing; 2022. Available from: https://www. ncbi.nlm.nih.gov/books/NBK554586 [Last accessed on 2024 Jan 27].

 

  1. Okada DR, Smith J, Derakhshan A, et al. Ventricular arrhythmias in cardiac sarcoidosis. Circulation. 2018;138:1253-1264. doi: 10.1161/CIRCULATIONAHA.118.034687

 

  1. Lehtonen J, Uusitalo V, Pöyhönen P, Mäyränpää MI, Kupari M. Cardiac sarcoidosis: Phenotypes, diagnosis, treatment, and prognosis. Eur Heart J. 2023;44:1495-1510. doi: 10.1093/eurheartj/ehad067

 

  1. Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac sarcoidosis. J Am Coll Cardiol. 2016;68:411-421. doi: 10.1016/j.jacc.2016.03.605

 

  1. Kakizaki R, Koitabashi T, Minami Y, et al. Untreated cardiac sarcoidosis with active inflammation: Severe left ventricular dysfunction and ventricular wall thinning in three years. J Cardiol Cases. 2017;16:141-143. doi: 10.1016/j.jccase.2017.06.006

 

  1. Di Stefano C, Bruno G, Arciniegas Calle MC, et al. Diagnostic and predictive value of speckle tracking echocardiography in cardiac sarcoidosis. BMC Cardiovascr Disord. 2020;20:21. doi: 10.1186/s12872-019-01323-0

 

  1. Cacoub P, Chapelon-Abric C, Resche-Rigon M, Saadoun D, Desbois AC, Biard L. Cardiac sarcoidosis: A long term follow up study. PLoS One. 2020;15:e0238391. doi: 10.1371/journal.pone.0238391

 

  1. Kaida T, Inomata T, Minami Y, et al. Importance of early diagnosis of cardiac sarcoidosis in patients with complete atrioventricular block. Int Heart J. 2018;59:772-778. doi: 10.1536/ihj.17-492

 

  1. Ekström K, Räisänen-Sokolowski A, Lehtonen J, Nordenswan HK, Mäyränpää MI, Kupari M. Idiopathic giant cell myocarditis or cardiac sarcoidosis? A retrospective audit of a nationwide case series. ESC Heart Fail. 2020;3:1362-1370. doi: 10.1002/ehf2.12725

 

  1. Divakaran S, Stewart GC, Lakdawala NK, et al. Diagnostic accuracy of advanced imaging in cardiac sarcoidosis. Circ Cardiovasc Imaging. 2020;12(6):e008975. doi: 10.1161/circimaging.118.008975

 

  1. Okafor J, Khattar R, Kouranos V, et al. Role of serial 18F-fludeoxyglucose positron emission tomography in determining the therapeutic efficacy of immunosuppression and clinical outcome in patients with cardiac sarcoidosis. J Nucl Cardiol. 2024;35:101842. doi: 10.1016/j.nuclcard.2024.101842

 

  1. Zhou Y, Lower EE, Li HP, Costea A, Attari M, Baughman RP. Cardiac sarcoidosis: The impact of age and implanted devices on survival. Chest. 2017;151:139-148. doi: 10.1016/j.chest.2016.08.1457

 

  1. Yodogawa K, Fukushima Y, Tachi M, et al. Localization of late gadolinium enhancement and its association with ventricular tachycardia in patients with cardiac sarcoidosis. Int Heart J. 2022;63:235-240. doi: 10.1536/ihj.21-635

 

  1. Crouser ED, Ono C, Tran T, He X, Raman SV. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med. 2014;189(1):109-112. doi: 10.1164/rccm.201309-1668LE

 

  1. Cheng RK, Kittleson MM, Beavers CJ, et al. Diagnosis and management of cardiac sarcoidosis: A scientific statement from the American Heart Association. Circulation. 2024;149(21):e1197-e1216. doi: 10.1161/cir.0000000000001240

 

  1. Kato Y, Morimoto S, Uemura A, Hiramitsu S, Ito T, Hishida H. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:133-137.

 

  1. Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: A systematic review. Can J Cardiol. 2013;29:1034-1041. doi: 10.1016/j.cjca.2013.02.004

 

  1. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006-1010. doi: 10.1016/s0002-9149(01)01978-6

 

  1. Gallegos C, Oikonomou EK, Grimshaw A, Gulati M, Young BD, Miller EJ. Non-steroidal treatment of cardiac sarcoidosis: A systematic review. Int J Cardiol Heart Vasc. 2021;34:100782. doi: 10.16/j.ijcha.2021.100782

 

  1. Ahmed R, Okafor J, Azzu A, et al. The role of infliximab in treating refractory cardiac sarcoidosis. Eur Heart J. 2023;44(Supplement_2):ehad655.978. doi: 10.1093/eurheartj/ehad655.978

 

  1. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):e210-e271. doi: 10.1016/j.jacc.2017.10.054

 

  1. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43:3997-4126. doi: 10.1093/eurheartj/ehac262

 

  1. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427-3520. doi: 10.1093/eurheartj/ehab364

 

  1. Mohsen A, Jimenez A, Hood RE, et al. Cardiac sarcoidosis: Electrophysiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2013;25:171-176. doi: 10.1111/jce.12302

 

  1. Nordenswan HK, Pöyhönen P, Lehtonen J, et al. Incidence of sudden cardiac death and life-threatening arrhythmias in clinically manifest cardiac sarcoidosis with and without current indications for an implantable cardioverter defibrillator. Circulation. 2022;13:964-975. doi: 10.1161/CIRCULATIONAHA.121.058120

 

  1. Kron J, Sauer W, Mueller G, et al. Outcomes of patients with definite and suspected isolated cardiac sarcoidosis treated with an implantable cardiac defibrillator. J Interv Card Electrophysiol. 2015;43:55-64. doi: 10.1007/s10840-015-9978-3

 

  1. Mactaggart S, Ahmed R. The role of ICDs in patients with sarcoidosis-A comprehensive review. Curr Probl Cardiol. 2024;49(5):102483. doi: 10.1016/j.cpcardiol.2024.102483

 

  1. Mathijssen H, Bakker ALM, Balt JC, et al. Predictors of appropriate implantable cardiac defibrillator therapy in cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2022;33:1272-1280. doi: 10.1111/jce.15484

 

  1. Azoulay LD, Waintraub X, Haroche J, Amoura Z, Cohen Aubart F. Factors associated with implantable cardioverter defibrillators appropriate therapy in cardiac sarcoidosis: A meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis. 2020;37:17-23. doi: 10.36141/svdld.v37i1.8271

 

  1. Franke KB, Marshall H, Kennewell P, et al. Risk and predictors of sudden death in cardiac sarcoidosis: A systematic review and meta-analysis. Int J Cardiol. 2021;328:130-140. doi: 10.1016/j.ijcard.2020.11.044

 

  1. Jefic D, Joel B, Good E, et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: Report from a multicenter registry. Heart Rhythm. 2009;6:189-195. doi: 10.1016/j.hrthm.2008.10.039

 

  1. Siontis KC, Santangeli P, Muser D, et al. Outcomes associated with catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis. JAMA Cardiol. 2022;7:175-183. doi: 10.1001/jamacardio.2021.4738

 

  1. Berte B, Sacher F, Venlet J, et al. VT recurrence after ablation: Incomplete ablation or disease progression? A multicentric European study. J Cardiovasc Electrophysiol. 2015;27:80-87. doi: 10.1111/jce.12858

 

  1. Stevenson WG, Soejima K. Catheter ablation for ventricular tachycardia. Circulation. 2007;115:2750-2760. doi: 10.1161/circulationaha.106.655720

 

  1. Muser D, Santangeli P, Pathak RK, et al. Long-term outcomes of catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2016;9:e004333. doi: 10.1161/CIRCEP.116.004333

 

  1. Ahmed R, Dulay MS, Liu A, et al. Comparing outcomes of an “early” versus “late” diagnosis of cardiac sarcoidosis following a baseline presentation of high-grade atrioventricular block. Curr Probl Cardiol. 2024;49(7):102577. doi: 10.1016/j.cpcardiol.2024.102577

 

  1. Nordenswan HK, Lehtonen J, Ekström K, et al. Outcome of cardiac sarcoidosis presenting with high-grade atrioventricular block. Circ Arrhythm Electrophysiol. 2018;11(8):e006145. doi: 10.1161/CIRCEP.117.006145

 

  1. Takaya Y, Kusano KF, Nakamura K, Ito H. Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac sarcoidosis. Am J Cardiol. 2015;115:505-509. doi: 10.1016/j.amjcard.2014.11.028
Share
Back to top
Brain & Heart, Electronic ISSN: 2972-4139 Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept